Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships
Jyong Biotech reaffirmed its strategic focus on pursuing global licensing partnerships for its urology therapeutics, specifically targeting the Benign Prostatic Hyperplasia (BPH) market. The company cited industry data estimating the global BPH treatment market could grow to $22.6 billion by 2035, driven by an aging population and high discontinuation rates of existing therapies.
Key figures
- Bph market size 2025
- $13 billion
- Phase iii trials count
- 4
- Bph market size 2035 proj
- $22 billion - $22.6 billion
- Bph patient population 2021
- 112.5 million
- Existing treatment discontinuation rate
- 60% - 90%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.